Ceramide/Sphingosine-1-phosphate in patients with Hypertension Compared with normotensive controls: a case-control Study

Ceramide/Sphingosine-1-phosphate in patients with Hypertension Compared with normotensive controls: a case-control Study - Ceramide/Sphingosine-1-phosphate in patients with Hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40437

Enrollment

Registered

2014-06-11

Start date

2014-09-10

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloeddrukregulatie Hypertension en verhoogde bloeddruk

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with age between 18 and 55 years with Grade 1 to 3 Hypertension

Exclusion criteria

Exclusion criteria: Pregnancy Use of statin medication Age under 18 years

Design outcomes

Primary

Measure	Time frame
The main study parameter is the subfraction of Ceramide/Sphingolipid-1-phosphate in serum plasma	—

Countries

Netherlands

Outcome results